The Epidemiology behind the HPV Vaccine Discovery

Annals of Epidemiology

Volumn 19, Issue 4, 2009, Pages 239-244

  Koutsky, Laura ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cervical Cancer; HPV Vaccine; HPV Related Cancer Epidemiology

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MOUTH CANCER; OROPHARYNX CANCER; PAPANICOLAOU TEST; PENIS CANCER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VAGINA CANCER; VERRUCA VULGARIS; VIRUS TRANSMISSION; VULVA CANCER;

EID: 63149134967     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2009.01.023     Document Type: Note

References (79)

1. Durst M., Gissmann L., Ikenberg H., and zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
2. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. Randomized clinical trial of human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 64 (1995), World Health Organization, Lyon, France
4. Bosch F.X., Manos M.M., Muñoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 796-802
5. Muñoz N., Bosch F.X., de Sanjosé S., et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
6. Daling J.R., Madeleine M.M., Johnson L.G., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101 (2004) 270-280
7. Daling J.R., Madeleine M.M., Schwartz S.M., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 84 (2002) 263-270
8. Rubin M.A., Kleter B., Zhou M., et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159 (2001) 1211-1218
9. Trimble C.L., Hildesheim A., Brinton L.A., et al. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol 87 (1996) 59-64
10. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
11. Rotkin I.D. Sexual characteristics of a cervical cancer population. Am J Public Health 57 (1967) 815-828
12. Terris M., Wilson F., Smith H., Sprung E., and Nelson J.H. The relationship of coitus to carcinoma of the cervix. Am J Public Health 57 (1967) 840-847
13. Zunzunegui M.V., King M.-C., Coria C.F., and Charlet J. Male influences on cervical cancer risk. Am J Epidemiol 123 (1986) 302-307
14. Brinton L.A., Reeves W.C., Brenes M.M., Herrero R., Gaitan E., Tenorio F., et al. The male factor in the etiology of cervical cancer among sexually monogamous women. Int J Cancer 44 (1989) 199-203
15. Reid B.L., French P.W., Singer A., Hagan B.E., and Coppleson M. Sperm basic proteins in cervical carcinogenesis: correlation with socioeconomic class. Lancet 2 (1978) 60-62
16. Furgyik S., and Astedt B. Gonorrheal infection followed by an increased frequency of cervical carcinoma. Acta Obstet Gynecol Scand 59 (1980) 521-524
17. Hulka B.S. Risk factors for cervical cancer. J Chron Dis 35 (1982) 3-11
18. Schacter J., Hill E.C., King E.B., Heilbron D.C., Ray R.M., Margolis A.J., et al. Chlamydia trachomatis and cervical neoplasia. JAMA 248 (1982) 2134-2138
19. Kessler II. Cervical cancer: social and sexual correlates. In: Banbury R.21, Peto R., and zur Hausen H. (Eds). Viral etiology of cancer (1986), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY) 55-64
20. de Villiers E.M., Gissmann L., and zur Hausen H. Molecular cloning of viral DNA from human genital warts. J Virol 40 (1981) 932-935
21. Gissmann L., de Villiers E.M., and zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer 29 (1980) 143-146
22. Boshart M., Gissmann L., Ikenberg H., Kleinheinz A., Scheurlen W., and zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3 (1984) 1151-1157
23. Crum C.P., Ikenberg H., Richart R.M., and Gissman L. Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med 310 (1984) 880-883
24. Prakash S.S., Reeves W.C., Sisson G.R., Breues M., Godoy J., Bacchetti S., et al. Herpes simplex virus type 2 and human papillomavirus type 16 in cervicitis, dysplasia and invasive cervical carcinoma. Int J Cancer 35 (1985) 51
25. Scholl S.M., Kingsley Pillers E.M., Robinson R.E., and Farrell P. Prevalence of human papillomavirus type 16 DNA in cervical carcinoma samples in East Anglia. Int J Cancer 35 (1985) 215
26. de Villiers E.-M., Schneider A., Gross G., and zur Hausen H. Analysis of benign and malignant urogenital tumors for human papillomavirus infection by labeling cellular DNA. Med Microbiol Immunol 174 (1986) 281
27. Lorincz A.T., Lancaster W.D., and Temple G.F. Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix. J Virol 58 (1986) 225-229
28. Pratili M.A., Le Doussal V., Harvey P., Laval C., Bertrand F., Jibard N., et al. Detection of human papillomavirus in epithelial cells of uterine cervix-frequency of types 16 and 18 HPV. Preliminary results of a clinical cytological and virological study. Chin Med J (Engl) 99 (1986) 815-820
29. Brandsma J.L., Steinberg B.M., Abramson A.L., and Winkler B. Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. Cancer Res 46 (1986) 2185-2188
30. Beckmann A.M., Myerson D., Daling J.R., Kiviat N.B., Fenoglio C.M., and McDougall J.K. Detection and localization of human papillomavirus DNA in human genital condylomas by in situ hybridization with biotinylated probes. J Med Virol 16 (1985) 265-273
31. de Villiers E.M., Weidauer H., Otto H., and zur Hausen H. Papillomavirus DNA in human tongue carcinomas. Int J Cancer 36 (1985) 575-578
32. McCance D.J., Clarkson P.K., Dyson J.L., Walker P.G., and Singer A. Human papillomavirus types 6 and 16 in multifocal intraepithelial neoplasias of the female lower genital tract. Br J Obstet Gynaecol 92 (1985) 1093-1100
33. Dyson N., Howley P.M., Münger K., and Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
34. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 (1990) 76-79
35. Barbosa M.S., and Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Ocogene 4 (1989) 1529-15
36. Koutsky L.A., Holmes K.K., Critchlow C.W., Stevens C.E., Paavonen J., Beckmann A.M., et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327 (1992) 1272-1278
37. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001) 1831-1836
38. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 (2001) 3106-3114
39. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
40. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738
41. Gustafsson L., and Adami H.O. Optimization of cervical cancer screening. Cancer Causes Control 3 (1992) 125-136
42. Zhou J., Sun X.Y., Stenzel D.J., and Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 (1991) 251-257
43. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89 (1992) 12180-12184
44. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67 (1993) 6929-6936
45. Breitburd F., Kirnbauer R., Hubbert N.L., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
46. Campo M.S., Grindlay G.J., O'Neil B.W., Chandrachud L.M., McGarvie G.M., and Jarrett W.F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74 (1993) 945-953
47. Suzich J.A., Ghim S.J., Palmer-Hill F.J., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 (1995) 11553-11557
48. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., and Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 307 (1984) 178-180
49. Xi L.F., Demers G.W., Koutsky L.A., et al. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 172 (1995) 747-755
50. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738
51. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.-K., Kuypers J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 (1996) 927-936
52. Negri G., Bellisano G., Zannoni G.F., Rivasi F., Kasal A., Vittadello F., et al. p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 32 (2008) 1715-1720
53. Watts D.H., Koutsky L.A., Holmes K.K., Goldman D., Kuypers J., Kiviat N.B., et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 178 (1998) 365-373
54. Cason J., Kaye J.N., Jewers R.J., Kambo P.K., Bible J.M., Kell B., et al. Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol 47 (1995) 209-218
55. Puranen M., Yliskoski M., Saarikoski S., Syrjänen K., and Syrjänen S. Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol 174 (1996) 694-699
56. Rice P.S., Cason J., Best J.M., and Banatvala J.E. High risk genital papillomavirus infections are spread vertically. Rev Med Virol 9 (1999) 15-21
57. Smith E.M., Johnson S.R., Cripe T., Perlman S., McGuinness G., Jiang D., et al. Perinatal transmission and maternal risks of human papillomavirus infection. Cancer Detect Prev 19 (1995) 196-205
58. Smith E.M., Ritchie J.M., Yankowitz J., Swarnavel S., Wang D., Haugen T.H., et al. Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex Transm Dis 31 (2004) 57-62
59. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
60. Moscicki A.B., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 (2001) 2995-3002
61. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226 Erratum in: Am J Epidemiol. 2003;157:858
62. Castle P.E., Schiffman M., Herrero R., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191 (2005) 1808-1816
63. Sycuro L.K., Xi L.F., Hughes J.P., Feng Q., Winer R.L., Lee S.K., et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 198 (2008) 971-978
64. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al., on behalf of the Proof of Principle Study Investigators. Efficacy of human papillomavirus-16 vaccine for preventing cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
65. Mao C., Hughes J.P., Kiviat N., et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol 188 (2003) 677-684
66. Brown D.R., Fife K.H., Wheeler C.M., Koutsky L.A., Lupinacci L.M., Railkar R., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 (2004) 2936-2942
67. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
68. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
69. Paavonen J., Jenkins D., Bosch F.X., et al., HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170 Erratum in: Lancet. 2007;370:1414
70. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al., Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
71. FUTURE II Study Group (corresponding author: Koutsky LA). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
72. Pedersen C., Petaja T., Strauss G., et al., HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571
73. Reisinger K.S., Block S.L., Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 (2007) 201-209
74. Collins S.I., Mazloomzadeh S., Winter H., et al. Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study. Int J Cancer 114 (2005) 498-500
75. Winer R.L., Feng Q., Hughes J.P., O'Reilly S., Kiviat N.B., and Koutsky L.A. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197 (2008) 279-282
76. Wellings K., Collumbien M., Slaymaker E., Singh S., Hodges Z., Patel D., et al. Sexual behaviour in context: a global perspective. Lancet 368 (2006) 1706-1728 Erratum in: Lancet. 2007;369:274
77. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
78. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
79. Goldie S.J., O'Shea M., Diaz M., and Kim S.Y. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 16 (2008) 86-96